Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer

Exclusion Criteria

• •Chemotherapy or radiotherapy within 3 weeks or within 5 half-lives of previous therapy
• •History of severe allergic or hypersensitivity reactions to taxanes.
• •Subjects who have not recovered from adverse events or toxicities due to agents administered more than 4 weeks earlier to a grade 1 or less
• •Not receiving any other study agents
• •History of or current coronary artery disease, myocardial infarction, angina pectoris, angioplasty or coronary bypass surgery.
• •Baseline QTc \> 470 msec or previous history of QT prolongation while taking other medications.
• •Ventricular ejection fraction of \< 55%.
• •History or current uncontrolled dysrhythmias, or requirement for antiarrhythmic medications, or Grade 2 or greater left bundle branch block.
• •ECG with clinically significant ventricular arrhythmias or ischemia
• •Major surgery within 4 weeks of starting treatment
• •Poor venous access necessitating use of indwelling catheter for IV therapy
• •Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance
• •History of another malignancy unless disease-free for 3 years and deemed to be at low risk for recurrence